Emcure Pharma Share Price Falls 5% After Heavy Block Deals; Key Details Inside

Emcure Pharmaceuticals share price (NSE: EMCURE) fell sharply on November 18, slipping 5% to an intra-day low of ₹1,325 on the BSE. Despite the fall in Emcure, the broader market remained positive, with the Sensex up 0.19% at 84,791.27.

Key Market Details

• Current Price: ₹1,355.7 on BSE (down 2.85%)
• Market Cap: ₹25,462.35 crore
• 52-Week Range: High ₹1,524.85 | Low ₹890
• Large Trades: 2.4% equity (4.64 million shares) exchanged via multiple block deals
• Buyers & Sellers: Not disclosed

Possible Stake Sale by Bain Capital

Reports indicated that Bain Capital affiliate BC Investments IV, which owned 6.3% of Emcure as of September 2025, was planning to sell around 2% stake through block deals.

• Estimated deal size: ₹493 crore
• Floor price: ₹1,296.5 per share

Promoters held 77.88% stake in the company at the end of September.

Company’s Recent Financial Performance

Emcure delivered strong results in Q2 FY26 Earnings Results:

• PAT: Up 25% YoY to ₹251 crore
• Revenue: Rose to ₹2,270 crore from ₹2,002 crore
• Growth drivers: Strong domestic and international business

The company is also strengthening its product portfolio through partnerships and in-house innovation. Its tie-up with Novo Nordisk positions it well in the rapidly growing obesity treatment segment.

Read More: Alert Car Buyers: Here Are 7 Must-Know FAQs to Save Up to 15% on Car Insurance!

About Emcure Pharma

Based in Pune, Emcure Pharmaceuticals is an R&D-focused company that develops, manufactures, and markets a wide range of medicines globally. The company is known for its innovation, quality standards, and patient-centric approach across multiple therapeutic areas.

Conclusion

Emcure Pharma’s share price came under pressure due to heavy block deals, likely linked to a stake sale by Bain Capital. Despite the short-term dip, the company’s strong financial growth and strategic partnerships continue to support its long-term outlook.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.